Impact News +++ Ayvens Backers Offer Stake Worth $1.1 Billion in Leasing Firm (Bloomberg) +++ AYVENS Aktie -5,90%

TG THERAPEUTICS Aktie

>TG THERAPEUTICS Aktienkurs

29.025 EUR -4.1% (Tradegate)

Ask: 29.295 EUR / 350 Stück

Bid: 28.995 EUR / 350 Stück

Tagesumsatz: 1673 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TG THERA Aktie über LYNX handeln

Intraday

1 Jahr

>TG THERAPEUTICS Performance

1 Woche: +7,6%

1 Monat: -0,1%

3 Monate: -2,8%

6 Monate: -22,8%

1 Jahr: +34,5%

laufendes Jahr: +0,4%

>TG THERAPEUTICS Aktie

Name:

TG THERAPEUTICS DL -,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US88322Q1085 / A1JXW7

Symbol/ Ticker:

NKB2 (Frankfurt) / TGTX (NASDAQ)

Kürzel:

FRA:NKB2, ETR:NKB2, NKB2:GR, NASDAQ:TGTX

Index:

Webseite:

http://www.tgtherapeutics..

Profil:

TG Therapeutics, Inc. is a biopharmaceutical compa..
>Volltext..

Marktkapitalisierung:

4782.9 Mio. EUR

Unternehmenswert:

4784.47 Mio. EUR

Umsatz:

393.55 Mio. EUR

EBITDA:

74.62 Mio. EUR

Nettogewinn:

52.4 Mio. EUR

Gewinn je Aktie:

0.36 EUR

Schulden:

219.9 Mio. EUR

Liquide Mittel:

111.92 Mio. EUR

Operativer Cashflow:

-51.24 Mio. EUR

Bargeldquote:

1.47

Umsatzwachstum:

19.08%

Gewinnwachstum:

-42.55%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

TG THERAPEUTICS, TG THERAPEUTIC, TG THERA

Letzte Datenerhebung:

03.11.25

>TG THERA Kennzahlen

Aktien/ Unternehmen:

Aktien: 158.67 Mio. St.

Frei handelbar: 90.08%

Leerverk. Aktien: 15.01%

Rückkaufquote: 0.37%

Mitarbeiter: 338

Umsatz/Mitarb.: 0.84 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 29.35%

Bewertung:

KGV: 90.16

KGV lG: 44.43

KUV: 12.18

KBV: 19.29

PEG-Ratio: -

EV/EBITDA: 64.12

Rentabilität:

Bruttomarge: 86.91%

Gewinnmarge: 13.31%

Operative Marge: 18.91%

Managementeffizenz:

Gesamtkaprendite: 10.95%

Eigenkaprendite: 26.63%

>TG THERA Peer Group

Es sind 597 Aktien bekannt.

>TG THERAPEUTICS Chart & Kurs - NASDAQ

>TG THERAPEUTICS News

03.11.25 - 15:54	Earnings Call Transkript: TG Therapeutics übertrifft im 3. Quartal 2025 die EPS-Prognose, Aktie gibt nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.11.25 - 13:12	TG Therapeutics EPS of $2.43, revenue of $161.71M beats by $9.54M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.10.25 - 12:33	TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update (GlobeNewswire EN)
	Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET...

28.10.25 - 12:33

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI (GlobeNewswire EN)

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and Day 15 dosing schedule for IV BRIUMVI® (ublituximab-xiiy), the company's novel, glycoengineered, anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS). The primary endpoint of this trial is non inferior exposure with respect to area under the curve (AUC) at week 16....

27.10.25 - 16:30	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
	TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

13.09.25 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von TG Therapeutics im Wert von 672268 USD (Insiderkauf)
	Lonial, Sagar - Aufsichtsrat - Tag der Transaktion: 2025-09-11...

10.09.25 - 13:33

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting (GlobeNewswire EN)

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 - 26, 2025 in Barcelona, Spain. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: ECTRIMS 2025 PROGRAMME. Details of the upcoming presentations are outlined below....

04.09.25 - 13:33	TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire EN)
	Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET...

03.09.25 - 19:48	TG Therapeutics announces $100M share buyback program (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.09.25 - 19:00	Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report? (Zacks)
	TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

03.09.25 - 13:33	TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program (GlobeNewswire EN)
	NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under that program, the Company repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share....

28.08.25 - 14:03	TG Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire EN)
	Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET...

08.08.25 - 23:36	TG Therapeutics files automatic mixed securities shelf (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.08.25 - 19:45	TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line (Zacks)
	TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales....

04.08.25 - 18:48	TG Therapeutics Q2 Revenue Up 91% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 17:18	TG Therapeutics falls after Q2 miss despite guidance raise (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 16:24	TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 16:00	TG Therapeutics (TGTX) Misses Q2 Earnings Estimates (Zacks)
	TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

04.08.25 - 13:06	TG Therapeutics misses top-line and bottom-line estimates; raises FY25 outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 13:03	TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire EN)
	Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer heilt, hat recht. - Hippokrates

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram